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Assessment of the initiation and tolerability 
of tapentadol prolonged-release therapeutics 
in patients with chronic pain in a chronic pain 
unit setting in Portugal: a cross-sectional study
Resumen
Introducción. El tapentadol de liberación prolongada (LP) es un analgésico de acción central indicado para 
el tratamiento del dolor moderado a intenso. El objetivo de este estudio es caracterizar la introducción y la 
tolerabilidad del tapentadol LP en pacientes seguidos en una unidad de dolor crónico mediante la evalua-
ción de la prevalencia de eventos adversos y las principales razones para la interrupción del tratamiento o 
la reducción de la dosis.
Material y métodos. En este estudio transversal, todos los pacientes seguidos en la unidad de dolor crónico 
bajo tratamiento con tapentadol LP fueron analizados durante un período de 8 meses. Las características 
demográficas y clínicas de los pacientes fueron recolectadas retrospectivamente a través de la consulta de 
los archivos clínicos.
Resultados. De los 127 pacientes incluidos en el estudio, 119 (93,7%) reemplazaron analgésicos opioides 
por tapentadol LP, siendo este el fármaco de primera línea en 8 (6,3%) pacientes. Durante el estudio, 26 
(20,5%) pacientes interrumpieron el tratamiento con tapentadol LP y 5 (3,9%) pacientes redujeron su 
dosis. Las principales razones para la interrupción de tapentadol LP fueron eventos adversos: náuseas 
o vómitos (32.1%), estreñimiento (19.2%), mareos (19.2%) y ausencia del efecto analgésico deseado.
Discusión. La prevalencia de la interrupción del tratamiento con tapentadol LP y los eventos adversos 
asociados con su uso fue similar a la descrita anteriormente. Se necesitarán más estudios para optimi-
zar el tratamiento de pacientes con dolor crónico tapentadol LP en el contexto de unidades de dolor 
crónico.
Conclusión. En nuestro estudio, los pacientes que suspendieron el tapentadol corresponden a un por-
centaje bajo. Encontramos que el motivo más frecuente fueron los efectos adversos gastrointestinales, 
seguidos por la falta de efecto analgésico y mareos. El tapentadol PR parece ser un fármaco bien tol-
erado por los pacientes seguidos en la unidad del dolor.
 
Abstract
Introduction. Tapentadol prolonged-release (PR) is a centrally acting oral analgesic prescribed for the treatment 
of moderate to severe pain. This study aimed to characterize the introduction and tolerability of tapentadol PR 
treatment in patients with chronic pain who were attending a hospital-based chronic pain outpatient unit, by 
assessing the prevalence and main reasons for treatment discontinuation or dose reduction.
Material and Methods. In this cross-sectional observational study, all patients visiting an outpatient chronic 
pain unit who were taking tapentadol PR as their analgesic therapy were included. Demographic and clinical 
data of patients, and reasons for tapentadol PR treatment discontinuation or reduction during an eight-month 
period were extracted from the medical records.
Results. Of the 127 enrolled patients, 119 (93.7%) were switched from opioids to tapentadol PR and 8 (6.3%) 
were taking tapentadol PR as their primary medication for the treatment of chronic pain. During the study, 26 
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INTRODUCTION
Chronic pain was defined as persistent or recurrent 
pain lasting longer than 3 months. Its incidence and fre-
quency increase with age, number of comorbidities, as 
well as the number of medications.  1 The pain is usually 
nociceptive, neuropathic or a mixture of the two.8 Opioid 
analgesics are recommended by the World Health Orga-
nization analgesic ladder for the treatment of moderate-
to-severe pain.2 Their main mechanism of analgesic action 
is the µ-opioid receptor agonism.3 However, the use of 
opioid analgesics has adverse reactions difficult to control 
such as nausea, vomiting, and constipation and are also 
associated with phenomena of analgesic tolerance and 
drug dependence.3 These factors may contribute to the 
abandonment of opioid analgesics therapeutics. For the-
se reasons, achieving and maintaining the balance between 
analgesia and safety difficult.9
Tapentadol hydrochloride is a centrally acting analgesic 
indicated for the treatment of chronic severe pain that acts in 
two ways: through the agonism of µ-opioid receptors, atte-
nuating the upward transmission in the pain pathway; and by 
inhibiting the reuptake of norepinephrine, leaving more free 
norepinephrine in the downward pain pathway which allows 
modulation of the painful stimulus.3-5 
The µ-opioid receptor binding affinity of the drug was 
considerably lower that of morphine in vitro, although its 
analgesic potency in animal models was only two- or three-
times lower than that of morphine, highlighting the con-
tribution of noradrenaline reuptake inhibitor activity to its 
analgesic effect.9 The dual mechanism of action of tapenta-
dol and its prolonged-release (PR) formulation reduces the 
intakes per day and allows for fewer drug side effects than 
equianalgesic doses of opioids.3,5,7 This might increase the 
therapeutic compliance in treating chronic pain of diverse 
etiologies.3,4This simplification of the therapeutic approach 
increases the patient’s adherence and compliance to the 
therapy. While tapentadol is a weak μ-opioid agonist, its 
use has several benefits: less opioid side-effects with equi-
potent analgesia,3,4 does not have active metabolites, does 
not induce hepatic cytochromes, nor has important binding 
to proteins.3 In addition, tapentadol PR low risk for intole-
rance and its low incidence of adverse reactions allows a 
faster dose titration, and hence, a faster and more effective 
pain control.7
This study aimed to characterize the introduction and 
tolerability of tapentadol PR therapeutics in patients with 
chronic pain, who attended a hospital-based outpatient 
unit for chronic pain over a period of 8 months, by asses-
sing the prevalence of treatment discontinuation and dose 
reduction, the main reasons for tapentadol PR discontinua-
tion, and the time to treatment discontinuation for each of 
the main reasons.
MATERIALS AND METHODS
In this cross-sectional observational study, we exami-
ned the medical records of outpatients who attended the 
Chronic Pain Unit in an eight-month period following the 
introduction of tapentadol PR therapeutics. Consecutive 
patients previously diagnosed with chronic pain (i.e., pain 
that persists beyond the usual course of an acute disease 
or after a reasonable time for healing to occur; this healing 
period typically can vary from 1 to 6 months)6 were included 
in the study. Inclusion criteria were: being 18 years old or 
older, and having at least one prescription for tapentadol PR. 
Patients were excluded if they had missing data regarding 
dates of initiation and/or discontinuation of tapentadol LR 
therapeutics, or died.
Collected demographic and medical variables were 
age, gender, and etiology of chronic pain (i.e. oncologic 
or non-oncologic). Data collection regarding the analgesic 
therapeutics included maximum daily dose and duration of 
tapentadol LR therapeutics, and existence of concomitant 
analgesic medication. The outcome measures for tolerability 
of tapentadol LR were: treatment discontinuation (stopping 
the use of tapentadol LR); dose reduction of tapentadol LR; 
main reasons for the discontinuation or dose reduction of 
tapentadol PR therapeutics (e.g., lack of analgesic effect, 
reduction of analgesic need, or intolerability because of ad-
verse reactions such as gastrointestinal, nervous system, skin 
or general disorders); and time to treatment discontinuation 
for each of main reasons. Categorical data were summarized 
as number (percentage) and continuous data as mean ± stan-
dard deviation (minimum-maximum) or median (minimum-
maximum). The statistical software SPSS version 22.0 for 
Windows (SPSS, Chicago, IL) was used to analyze the data.
This study conformed with the principles outlined in 
the Helsinki Declaration and was approved by the Ethics 
Committee of Centro Hospitalar Tondela-Viseu.
RESULTS
Out of 135 patients who were attending the outpatient 
unit and have been treated with tapentadol PR for chronic 
pain between March and November 2014, 8 patients were 
excluded. Seven patients were excluded because of incom-
plete data, and one patient died. The demographic char-
acteristics of the 127 patients included in our study were: 
mean age of 63.0 ± 13.6 (32-91) years old, and mostly female 
(72.4%, n = 92). The most common cause of chronic pain 
was non-oncologic (84.3%, n = 107). At study entry, most pa-
tients had switched from opioids to tapentadol PR and main-
tained concomitant analgesic medications (93.7%, n = 119), 
whereas 8 patients were taking tapentadol PR as the first-
choice medication for the treatment of chronic pain. The 
(20.5%) patients discontinued tapentadol PR treatment and 5 (3.9%) patients reduced their dose. The most 
frequently reported reasons for tapendadol PR discontinuation were adverse reactions – nausea or vomiting 
(32.1%), constipation (19.2%), dizziness (19.2%) – and lack of analgesic effect (30.8%).
Discussion. Prevalence of treatment discontinuation and adverse reactions associated with the use of tapenta-
dol PR are similar to the ones previously reported. Further studies are needed to improve the management of 
chronic pain patients with tapentadol PR in an outpatient setting.
Conclusion. Patients with chronic pain in our study discontinued their tapentadol PR treatment at a low per-
centage. We found that the most frequent reason for discontinuation of tapentadol PR was gastrointestinal 
disorders, followed by lack of analgesic effect, and dizziness. Tapentadol PR appears to be a well-tolerated for 
the control of chronic pain in patients attending an outpatient unit. 
Funding: Grunenthal S.A. contributed with a grant to support Scientific Toolbox Consulting regarding medical 
writing services.
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starting dose of tapentadol PR used was twice-daily 50 mg in 
most patients with titration to effective analgesic dose. The 
mean maximum daily dose of tapentadol PR for all patients 
was 172.4 ± 91.2 (100-400) mg/day in two divided doses.
Table 1 shows the prevalence and characteristics of 
chronic pain patients who discontinued, reduced the dose, or 
continued the treatment with tapentadol PR. At eight months, 
the prevalence of all-cause treatment discontinuation and 
dose reduction of tapentadol PR was 20.5% (n = 26) and 3.9% 
(n = 5), respectively. All 31 patients who discontinued or re-
duced the dose of tapentadol PR used concomitant analgesic 
medication (e.g., paracetamol, anti-inflammatory drugs, anti-
epileptic drugs, antidepressants), and most of these patients 
were being treated for non-oncologic chronic pain (n = 28). 
Overall, the main reasons for treatment discontinuation were 
adverse reactions (16.5%, n = 21), lack of analgesic effect 
(6.3%, n = 8), or reduction of analgesic needs (0.8%, n = 1).
The reasons that led to treatment discontinuation or 
dose reduction of tapentadol PR are summarized in Table 2. 
During the study period, 53.8% (n = 14) of patients who dis-
continued tapentadol PR reported gastrointestinal disorders, 
which included nausea or vomiting (n = 6), constipation (n = 4), 
diarrhea (n = 2), and gastric discomfort (n = 2); and 30.8 % (n = 
8) of patients reported lack of analgesic effect. 
Other reasons that led to discontinuation of tapentadol 
PR treatment were dizziness (n = 5), legs edema (n = 2), reduc-
tion of analgesic needs because of reduction in patients’ pain 
severity (n = 1), among others (e.g., urinary incontinence, pru-
ritus, feeling hot, lethargy, headache, dyspnea). 
On the other hand, reported main reasons leading to 
dose reduction of tapentadol PR were: constipation (n = 1), 
reduction of analgesic needs (n = 1), dyspnea (n = 1), and con-
fusion (n = 1).
Table 1. Demographic and clinical characteristics of patients with chronic pain who discontinued, reduced the dose, or continued the 
tapentadol prolonged-release (PR) treatment.
Tapentadol PR treatment (n = 127)
Characteristic Discontinuation Dose reduction Continuation
No. of patients (%) 26 (20.5) 5 (3.9) 96 (75.6)
Female, n (%) 20 (15.7) 4 (3.1) 68 (53.5)
Etiology of chronic pain, n (%)
   Oncologic 3 (2.4) 0 (0.0) 17 (13.4)
   Non oncologic 23 (18.1) 5 (3.9) 79 (62.2)
Analgesic medication, n (%)
   Tapentadol PR alone 0 (0.0) 0 (0.0) 8 (6.3)
   Tapentadol PR with concomitant analgesic drugs 26 (20.5) 5 (3.9) 88 (69.3)
Tapentadol PR treatment
Event Discontinuation (n = 26) Dose reduction (n = 5)
Adverse reaction, n (%) 21 (80.8) 1 (24.2)
  Gastrointestinal disorders 14 (53.8) 1 (24.2)
     Nausea/vomiting 6 (23.1)
     Constipation 4 (15.4) 1 (24.2)
     Diarrhea 2 (7.7)
     Gastric discomfort 2 (7.7)
  Dizziness 5 (19.2) -
  Legs edema 2 (7.7) -
Lack of analgesic effect, n (%) 8 (30.8)
Reduction of analgesic needs, n (%) 1 (3.8) 1 (24.2)
Other/unknown, n (%) 7 (26.9) 2 (40.0)
Table 2. Reasons for discontinuation or dose reduction of tapentadol prolonged-release (PR) treatment in patients with chronic pain.
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Mean time to treatment discontinuation with tapentadol PR 
for all patients was 42.4 ± 41.2 (1-120) days (n = 26). Six patients with-
drew during the first week of tapentadol PR therapeutics, because 
of nausea, constipation, or dizziness, whereas 4 patients tolerated 
longest treatment periods of 110 to 120 days before discontinuation. 
These patients reported lack of analgesic effects as the main reason 
for discontinuation and resumed their previous opioid therapy.
Table 3 shows the duration and median maximum daily 
dose of tapentadol PR treatment for the most common reasons 
for discontinuation. Gastrointestinal disorders led to tapentadol 
PR discontinuation after average of 25.8 ± 27.6 days of treatment 
(n = 14), dizziness led to discontinuation after an average of 23.4 
± 36.8 days (n = 5), and lack of analgesic effects led to discontinu-
ation after an average of 62.0 ± 49.1 days of treatment (n = 8).
DISCUSSION
This was the first study that investigated the introduction 
and tolerability of tapentadol PR for chronic pain treatment in 
outpatients attending a chronic pain unit in Portugal. In these pa-
tients, maximum daily dose of tapentadol PR ranged from 100 to 
400 mg/day and duration of treatment was 1 to 120 days. Preva-
lence of all-cause treatment discontinuation and dose reduction 
for tapentadol PR was 20.5% and 3.9%, respectively. These were 
primarily due to adverse reactions and lack of analgesic effect.
Tapentadol PR use for up to 2 years has been reported to be 
generally well tolerated in the clinical trials, pooled analyses and 
clinical practice studies. 9 
In our study, we found that the prevalence of tapentadol 
PR discontinuation owing to adverse reactions is 16.5%, which 
was similar to those of other studies about the tolerability of 
tapentadol in pain therapeutics (13-22%).3,4 Moreover, we show 
that the most frequent adverse effects associated with the use 
of tapentadol PR reported in our unit - nausea, vomiting, cons-
tipation, dizziness - are similar to the ones described in previous 
studies, being these less frequent than those of other opioids.3-5 
We also found other commonly described reasons for disconti-
nuation (i.e., pruritus, feeling hot, and lethargy),3 as well as less 
frequently reported adverse reactions (i.e., legs edema, urinary 
incontinence, and dyspnea).
Several limitations may be presented for our study. We in-
cluded in our study all patients that were available to us from a 
single unit, and no sample size calculation was carried out. There-
fore, results from our study may not necessarily be generalized to 
other settings, or for patients with different clinical backgrounds. 
For instance, further studies with tapentadol PR should include 
more representative subsamples of patients with different etio-
logies for chronic pain.
In conclusion, we found that the most frequent reason for 
discontinuation of tapentadol PR was gastrointestinal disorders, 
followed by lack of analgesic effect, and dizziness. Patients dis-
continued their tapentadol PR treatment at a non-negligible per-
centage, but, in most of the cases, this medication was well-tole-
rated by these patients in an outpatient chronic pain unit setting.
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Treatment Gastrointestinal disorders (n = 14)
Dizziness 
(n = 5)
Lack of analgesic effect  
(n = 8)
Time to discontinuation, mean ± SD 
(min-max), days 25.8 ± 27.6 (1-89) 23.4 ± 36.8 (1-87) 62.0 ± 49.1 (11-120)
Maximum daily dose, median 
(min-max), mg 100 (100-200) 100 (100-200) 200 (100-400)
Table 3. Duration and daily dose of tapentadol prolonged-release treatment before discontinuation owing to the most frequent adverse 
effects in patients with chronic pain.
